Biote's second quarter 2025 performance showed a slight year-over-year revenue decrease to $48.9 million, but a significant improvement in profitability with net income reaching $3.9 million compared to a loss in the prior year. Adjusted EBITDA increased by 19.1% to $15.2 million, with the margin expanding to 31.1%, primarily due to the shift of their annual marketing event and efficiency gains from vertical integration.

Biote reported a total revenue of $49.0 million for the first quarter of 2025, a 4.7% increase year-over-year. Net income was $15.8 million, a significant improvement from a net loss in the prior year. Gross profit margin increased to 74.3%, primarily due to vertical integration and cost management. Adjusted EBITDA was $13.8 million.

Biote's Q4 2024 revenue reached $49.8 million, marking a 9.0% increase year-over-year. The company achieved a gross profit margin of 71.8% and reported a net income of $3.5 million. Adjusted EBITDA grew to $15.1 million, reflecting a strong 30.3% margin. However, procedure revenue growth was impacted by clinic software transitions and training focus.

Biote reported a 12.8% increase in third-quarter revenue, driven by procedure revenue growth and a strong return to growth in the dietary supplements business. The company saw a solid improvement in gross profit margin due to cost savings from vertical integration of manufacturing. Net income was $12.7 million, and adjusted EBITDA increased by 15.4% compared to the third quarter of 2023.

Biote reported revenue of $49.2 million, a slight decrease from the previous year. Procedure revenue increased, but dietary supplement revenue declined. The company experienced a net loss of $(10.5) million, influenced by increased investments in sales and marketing and changes in the fair value of earnout liabilities.

Biote reported a 4.4% increase in revenue to $46.8 million, driven by a 6.6% increase in procedure revenue. The company's gross profit margin increased by approximately 240 basis points to 71.4%. Net loss was $(5.8) million, with a loss per share of $(0.06). Adjusted EBITDA increased by 8.0% to $14.2 million.

Biote reported a 2.7% increase in revenue to $45.7 million for Q4 2023, driven by a 6.6% increase in procedure revenue. Net income was $12.1 million, with diluted earnings per share of $0.18. The company's gross profit margin improved to 69.4%.

Biote reported an 8.5% increase in revenue to $45.6 million and a net income of $19.6 million for the third quarter of 2023. The company's Adjusted EBITDA increased by 14.7% to $14.0 million.

Biote reported a 19.1% increase in revenue, reaching $49.3 million, driven by procedure and dietary supplement revenue growth. The company's gross profit margin increased by 60 basis points to 67.9%. Net loss was $(13.1) million, with a GAAP loss per share of $(0.25). Adjusted EBITDA increased by 10.6% to $14.5 million.

Biote reported a 20.7% increase in revenue to $44.8 million for Q1 2023. The company launched a new initiative targeting the men's health market and maintained its 2023 financial guidance.

Biote reported a strong fourth quarter and full year 2022, with revenue reaching $44.5 million, an 18.5% increase year over year, and net income of $12.8 million, or $0.18 per diluted share. The company's Adjusted EBITDA increased by 40% to $13.1 million. For the full year, revenue was $165.0 million, and Adjusted EBITDA was $50.1 million.

Biote reported an 18% increase in revenue to $42.0 million and a 19% increase in Adjusted EBITDA to $12.2 million compared to the third quarter of 2021. Despite hurricane-related clinic closures in key markets, the company's performance reflects the expansion of its clinic and practitioner network. Biote is on track to achieve the upper end of its 2022 financial guidance.